Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 18/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 8/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 3/20 | 1.00 |
| ▸ | BCR | P11274 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danusertib SCHEMBL466509 | 1.00 | AURKA (1.00) | AURKAAURKBABL1CDK2NTRK1 | |
| Danusertib SCHEMBL29453494 | 0.99 | AURKA (0.98) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL25277403 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL26184014 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL1377925 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL9998664 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL3486749 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL3486691 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL1377947 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL2922037 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-12378302-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20250195514-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2025-06-19 | — | — | US | disclosed |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | FOUNDATION MEDICINE, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MEDICINE, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-104072498-A | Synthetic method for (R)-N-[5-(2-methoxy-2-phenylacetyl)-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole-3-yl]-4-(4-methyl piperazine-1-yl)benzamide | UNIV SHENYANG PHARMACEUTICAL | 2014-10-01 | — | — | CN | disclosed |
| US-8809337-B2 | Carbamoyl derivatives of bicyclic carbonylamino-pyrazoles as prodrugs | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| WO-2014113729-A2 | METHODS OF TREATING CHOLANGIOCARCINOMA | FOUNDATION MECICINE, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014071419-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8669289-B2 | Methods and compositions relating to hematologic malignancies | THE JACKSON LABORATORY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-08-08 | — | — | US | disclosed |
| US-20120114605-A1 | METHODS AND COMPOSITIONS RELATING TO HEMATOLOGIC MALIGNANCIES | THE JACKSON LABORATORY | 2012-05-10 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20100022553-A1 | Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195514-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | AURKA 766/4885AURKB 711/4885AURKC 62/4885 |
| US-20230372338-A1 | METHODS OF TREATING CHOLANGIOCARCINOMA | HCCS, PNLIP, LIPA | AURKA 766/4885AURKB 711/4885AURKC 62/4885 |
| US-20100022553-A1 | Therapeutic Combination Comprising an Aurora Kinase Inhibitor and Imatinib | ABL1, AURKC, AURKA | AURKA 3/4885AURKB 4/4885AURKC 2/4885 |
| US-20250340615-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3234/4885AURKB 1682/4885AURKC 2279/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3234/4885AURKB 1682/4885AURKC 2279/4885 |
| US-12378302-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | AURKA 3122/4885AURKB 1445/4885AURKC 2211/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3234/4885AURKB 1682/4885AURKC 2279/4885 |
| US-20130203770-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | AURKA 84/4885AURKB 126/4885AURKC 115/4885 |
| US-12274699-B2 | Methods of treating cholangiocarcinoma | HCCS, PNLIP, LIPA | AURKA 766/4885AURKB 711/4885AURKC 62/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | AURKA 84/4885AURKB 126/4885AURKC 115/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | AURKA 3122/4885AURKB 1445/4885AURKC 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.